What is Pivot Bio?
Founded in 2010, Pivot Bio operates at the intersection of biotechnology and industrial agriculture. The company specializes in engineering microbes that colonize the roots of cereal crops, effectively converting atmospheric nitrogen into a form that plants can readily absorb. By reducing the reliance on traditional, energy-intensive synthetic fertilizers, Pivot Bio addresses critical environmental challenges while simultaneously improving yield efficiency for farmers. Its market position is defined by its ability to bridge the gap between laboratory-scale synthetic biology and large-scale commercial farming, making it a key player in the global transition toward net-zero agricultural practices.
How much funding has Pivot Bio raised?
Pivot Bio has raised a total of $616.7M across 5 funding rounds:
Private Equity
$749K
Series A
$16M
Series B
$70M
Series C
$100M
Series D
$430M
Private Equity (2014): $749K, investors not publicly disclosed
Series A (2016): $16M, investors not publicly disclosed
Series B (2018): $70M supported by Breakthrough Energy Ventures and Temasek
Series C (2020): $100M featuring DCVC Management, Bunge Ventures, CGC, Alan Cohen, Spruce Capital Partners, Prelude Ventures, Breakthrough Energy Ventures, Tekfen Ventures, Pavilion Capital, Codon Capital, Roger Underwood, and Temasek
Series D (2021): $430M, investors not publicly disclosed
Key Investors in Pivot Bio
Breakthrough Energy Ventures
A mission-driven investment firm backed by global business leaders, focusing on companies that can significantly reduce emissions across agriculture, energy, and manufacturing sectors.
Temasek
A global investment company headquartered in Singapore that operates as a generational investor, prioritizing long-term value creation and sustainable development.
DCVC Management
A deep tech venture capital firm that leverages artificial intelligence and scientific breakthroughs to solve complex challenges in biotechnology and agriculture.
What's next for Pivot Bio?
With the infusion of $430M, Pivot Bio is well-positioned to expand its commercial footprint and deepen its research and development capabilities. The company is expected to focus on scaling its manufacturing infrastructure to meet rising global demand for sustainable agricultural inputs. Furthermore, the strategic backing from climate-focused investors suggests a long-term roadmap centered on carbon footprint reduction and the integration of its microbial solutions into broader regenerative farming ecosystems. As the firm moves into its next phase of maturity, the focus will likely shift toward international market penetration and the diversification of its product portfolio to include a wider range of crop types.
See full Pivot Bio company page
